LingVo.club
Level
Study finds Abbott-Bioline malaria test gives many false negatives — Level A2 — A woman standing in front of a hut

Study finds Abbott-Bioline malaria test gives many false negativesCEFR A2

14 Nov 2025

Level A2 – High beginner / Elementary
3 min
153 words

Rapid diagnostic tests help treat malaria quickly, especially in remote places without labs. The World Health Organization says about 4 million people a year are affected by malaria in Southeast Asia. Researchers from the Shoklo Malaria Research Unit did a study on the Thailand–Myanmar border between October 2024 and January 2025. They compared Abbott-Bioline with another rapid test and with microscopy.

The SMRU team reported that Abbott-Bioline detected only 18% of Plasmodium falciparum infections and 44% of Plasmodium vivax infections confirmed by microscopy. Many positive cases made only a faint line on the device, even when patients had fever. The study authors said the test is "not fit for purpose" and called for its removal. Abbott said its review found the tests were "performing as intended" and a WHO-qualified lab confirmed the company findings. WHO has reviewed reports since August 2024 and issued a notice on 31 March 2025.

Difficult words

  • malariaa dangerous disease spread by mosquitoes.
  • testa method to check for something.
  • diagnosingfinding out what is wrong with someone.
  • recommendto suggest someone do something.
  • false-negativenot showing something is true when it is.
  • researcherspeople who study a topic to learn more.
  • discoverto find out something new.
    discovered

Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.

Discussion questions

  • Why is it important to have accurate tests for diseases?
  • How can false-negative results affect patients?
  • What alternatives to the current test might work better?

Related articles

Tofersen slows a rare form of ALS — Level A2
26 Dec 2025

Tofersen slows a rare form of ALS

A long-term study shows that tofersen, a drug for a rare genetic form of ALS, can slow disease progression and help some people improve. The trial followed participants for several years and recorded benefits and side effects.